Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Centogene N.V. (NQ: CNTG )

0.3250 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Centogene N.V.

< Previous 1 2 3 4 5 Next >
CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
From Centogene NV
Via GlobeNewswire
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology
From Centogene NV
Via GlobeNewswire
CENTOGENE Receives Delisting Notice From Nasdaq
From Centogene NV
Via GlobeNewswire
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors
From Centogene NV
Via GlobeNewswire
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
From Centogene NV
Via GlobeNewswire
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
From Centogene NV
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday and we have them covered with our breakdown of all the latest news this morning! 
Via InvestorPlace
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
From Centogene NV
Via GlobeNewswire
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
Expanding Relationship With Lifera, a Biopharma Company Owned by the PIF 
From Centogene NV
Via GlobeNewswire
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
From Centogene NV
Via GlobeNewswire
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
Fueling the diagnosis of over 2,500 rare and neurodegenerative diseases, more than 300 peer-reviewed publications, and 48 pharma collaborations 
From Centogene NV
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Friday is here and we're breaking down the biggest pre-market stock movers that traders need to know about this morning! 
Via InvestorPlace
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CENTOGENE Receives Nasdaq Non-Compliance Notice
From Centogene NV
Via GlobeNewswire
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
From Centogene NV
Via GlobeNewswire
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected 
From Centogene NV
Via GlobeNewswire
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities 
From Centogene NV
Via GlobeNewswire
CENTOGENE Explores Strategic Alternatives
From Centogene NV
Via GlobeNewswire
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development 
From Centogene NV
Via GlobeNewswire
CENTOGENE Receives French Research Tax Credit Accreditation
Partners able to claim up to 30% tax relief 
From Centogene NV
Via GlobeNewswire
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
Collaboration to accelerate research to determine role of GBA gene 
From Centogene NV
Via GlobeNewswire
CENTOGENE Announces Preliminary Full Year 2023 Revenue
From Centogene NV
Via GlobeNewswire
CENTOGENE Announces Voting Results of Extraordinary General Meeting
From Centogene NV
Via GlobeNewswire
CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
From Centogene NV
Via GlobeNewswire
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
From Centogene NV
Via GlobeNewswire
CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism
Results From Landmark Study Published in Brain Journal 
From Centogene NV
Via GlobeNewswire
CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering
Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology 
From Centogene NV
Via GlobeNewswire
CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Centogene NV
Via GlobeNewswire
CENTOGENE Reports First Half 2023 Financial Results
Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance 
From Centogene NV
Via GlobeNewswire
CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients
From Centogene NV
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.